Tumores Gastrintestinais
M-A | Risco de desenvolvimento de câncer de vesícula biliar em pacientes com pólipos vesiculares detectados em ultrassonografia transabdominal.
18 Jul, 2022 | 12:30hRisk of developing gallbladder cancer in patients with gallbladder polyps detected on Trans-Abdominal ultrasound: a systematic review and Meta-Analysis – British Journal of Radiology (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
Critical Analysis of the Updated Guidelines for Management of Gallbladder Polyps – Annals of Surgical Oncology (se o acesso a este link for pago, tente este)
Estudo randomizado | Cabozantinibe com atezolizumabe vs. sorafenibe para carcinoma hepatocelular avançado.
11 Jul, 2022 | 13:45hComentário convidado: Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy – The Lancet Oncology (necessário cadastro gratuito)
Comentário no Twitter
In the phase III COSMIC-312 trial in 837 pts with advanced-stage HCC, mPFS was 6.8 vs 4.2 months (HR 0.63; P=.0012) & mOS was 15.4 vs 15.5 months (HR 0.90; P=.44) with cabozantinib+atezolizumab vs sorafenib; mPFS with cabozantinib alone was 5.8 months: https://t.co/eiZEqSxLAr
— NatureRevClinOncol (@NatRevClinOncol) July 6, 2022
Estudo de rastreamento multicêntrico de câncer de pâncreas: impacto sobre estágio e sobrevida.
6 Jul, 2022 | 10:54h
Comentário no Twitter
👀 The Cancer of Pancreas Screening (CAPS) program achieves early #PancreaticCancer detection and long-term survival with surveillance ➡️ https://t.co/flqUtSvkcg #JCO #pancSM @mggoggins pic.twitter.com/wj6DMXclVC
— Journal of Clinical Oncology (@JCO_ASCO) June 30, 2022
M-A | Fatores de risco de fístula pancreática pós-operatória clinicamente relevante após pancreatoduodenectomia.
6 Jul, 2022 | 10:41hDiretriz rápida da UEG e EAES sobre excisão mesorretal total transanal para câncer retal.
4 Jul, 2022 | 12:14hEstudo randomizado | Oxaliplatina (3 meses vs. 6 meses) com 6 meses de fluoropirimidina como terapia adjuvante em pacientes com câncer de cólon estágios II/III.
4 Jul, 2022 | 11:54hEstudo randomizado | Efeitos da estratégia perioperatória de “enhanced recovery” após esofagectomia minimamente invasiva.
4 Jul, 2022 | 11:51hConteúdos relacionados:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Resumo visual: ASO Visual Abstract: Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery—ERAS and Esophagectomy
Enhanced recovery after surgery (ERAS) programs for esophagectomy – Journal of Thoracic Disease
Estudo randomizado | Em pessoas vivendo com HIV, o tratamento de lesões anais pré-cancerosas reduz mais da metade do risco de câncer anal.
22 Jun, 2022 | 21:45hComunicado de imprensa: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health
Estudo original: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Randomized trial showed that treating anal high-grade squamous intraepithelial lesions (HSILs) led to a 57% reduction in progression to anal cancer as compared with active surveillance. https://t.co/iulcskP61C pic.twitter.com/Q6Oqty3hgW
— NEJM (@NEJM) June 15, 2022
Análises clínicas e imunológicas de estudo de fase II | Sotigalimabe e/ou nivolumabe com quimioterapia no câncer pancreático metastático.
22 Jun, 2022 | 20:43hComunicado de imprensa: Promising results for chemo-immunotherapy combination against pancreatic cancer, Penn study finds – University of Pennsylvania
Comentário no Twitter
At #ASCO22 Symposium on targeted therapy in GI cancer?
Check out the results & biomarker analysis of the phase 2 PRINCE trial on a CD40 agonist, nivolumab and chemotherapy in #PancreaticCancer, led by speaker @laceykitch @parkerici
Published today 👉 https://t.co/8aUXuvDHIC
— Nature Medicine (@NatureMedicine) June 3, 2022